|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Zentalis Pharmaceuticals, Llc (ZNTL) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
84,924,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
22,000 |
22,000 |
| Total Buy Value |
$0 |
$0 |
$219,391 |
$219,391 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
3,356 |
32,218 |
167,164 |
362,029 |
| Total Sell Value |
$42,353 |
$375,045 |
$4,063,616 |
$8,774,551 |
| Total People Sold |
1 |
5 |
8 |
8 |
| Total Sell Transactions |
1 |
7 |
13 |
35 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skvarka Jan |
Director |
– • – |
2023-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
16,364 |
52,970 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-05-31 |
4 |
AS |
$26.21 |
$729,506 |
D/D |
(27,768) |
463,502 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2023-05-26 |
4 |
AS |
$30.02 |
$2,401,248 |
I/I |
(80,000) |
15,000 |
|
- |
|
| Hausman Diane |
Director |
– • – |
2023-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
39,732 |
39,732 |
|
- |
|
| Roth Iris |
Chief Operating Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
52,500 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2023-02-14 |
4 |
AS |
$19.98 |
$104,411 |
D/D |
(5,227) |
392,048 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-02-14 |
4 |
AS |
$19.96 |
$169,706 |
D/D |
(8,501) |
491,270 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2023-02-14 |
4 |
AS |
$19.98 |
$129,873 |
D/D |
(6,500) |
865,157 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2023-02-13 |
4 |
AS |
$20.42 |
$53,594 |
D/D |
(2,624) |
397,275 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-02-13 |
4 |
AS |
$20.42 |
$68,054 |
D/D |
(3,332) |
499,771 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2023-02-13 |
4 |
AS |
$20.42 |
$77,756 |
D/D |
(3,807) |
871,657 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-02-06 |
4 |
AS |
$22.22 |
$222,678 |
D/D |
(10,000) |
503,103 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
101,957 |
399,899 |
|
- |
|
| Blackwell Kimberly |
Chief Executive Officer |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
244,800 |
249,800 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
91,354 |
875,464 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
161,092 |
513,103 |
|
- |
|
| Brownstein Carrie |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,313 |
116,313 |
|
- |
|
| Paul Andrea |
General Counsel |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,783 |
40,783 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-01-17 |
4 |
AS |
$24.11 |
$241,515 |
D/D |
(10,000) |
352,011 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2023-01-05 |
4 |
AS |
$21.01 |
$210,228 |
D/D |
(10,000) |
362,011 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2022-11-15 |
4 |
AS |
$22.72 |
$284,683 |
D/D |
(12,500) |
372,011 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2022-11-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
784,110 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2022-11-08 |
4 |
AS |
$23.56 |
$291,543 |
D/D |
(12,374) |
384,511 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2022-11-07 |
4 |
AS |
$23.66 |
$295,860 |
D/D |
(12,500) |
396,885 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2022-10-17 |
4 |
AS |
$23.51 |
$293,879 |
D/D |
(12,500) |
409,385 |
|
- |
|
237 Records found
|
|
Page 2 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
